brevifoliol | 134955-83-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: brevifoliol
• 英文别名: [(2S,4R,5R,5aS,6S,8S,9aR,10aS)-5,6-diacetyloxy-2,8-dihydroxy-10a-(2-hydroxypropan-2-yl)-3,5a-dimethyl-9-methylidene-2,4,5,6,7,8,9a,10-octahydro-1H-benzo[g]azulen-4-yl] benzoate
• CAS: 134955-83-2
• 化学式: C₃₁H₄₀O₉
• 分子量: 556.653
• InChiKey: VWGCDYGRSUJYGJ-GPOPEEISSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  40
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  140
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  brevifoliol 在 吡啶 、 咪唑 、 四氧化锇 、 3 A molecular sieve 、 4 A molecular sieve 、 N-甲基吗啉氧化物 作用下， 以 二氯甲烷 、 丙酮 、 叔丁醇 为溶剂， 反应 62.0h， 生成 13α-acetyl-20-tert-butyldimethylsilyloxy-5-methanesulfonyl-4α-hydroxybrevifoliol
  参考文献：
  名称：

  Characterization of an abeo-Taxane:  Brevifoliol and Derivatives

  摘要：

  Brevifoliol is a natural diterpene isolated from Taxus baccata Nutt. A series of brevifoliol 1 derivatives, 2-8 and 10, were prepared for characterization and semisynthesis purposes and included the introduction of acetyl, Troc, and TES groups at C-5 and C-13. Derivatives 16-20 of 5-acetylbrevifoliol 2 were obtained via esterification with cinnamic acid, with both 2S-(-)- and 2R-(+)-3-phenyllactic acid, and with N-benzoyl(2'R,3'S)-3'-phenylisoserine at C-13. Brevifoliol compounds 12, 13, and 15 with either 2S-(-)-phenyllactate moieties at C-5 and C-13 or an N-benzoyl-(2'R,3'S)-3'-phenylisoserinyl at C-13 were also prepared. An abeo-taxane structure for 1 was clearly defined from the C-13 NMR analysis of the 5-acetyl-13-oxo derivative 8 and from the conversion of 1 into 10, a conformationally restrained compound having a C-13, C-15 oxygen bridge. The biological activity of each of these derivatives is being studied.

  DOI：

  10.1021/np0304565

文献信息

• Tumor Homing Statin Derivatives
  申请人：Da Zen Theranostics, Inc.

  公开号：US20210008217A1

  公开（公告）日：2021-01-14

  The present invention generally relates to tumor homing statin derivatives (THSD) and their use for therapy, in particular cancer therapy. These THSD comprise three moieties: a statin moiety which comprises a dihydroxyheptanoic acid unit (DHHA) fixated by linkage into its open chain form, a heptamethine carbocyanine dye (HMCD) moiety, and a linker that conjugates the DHHA of the statin to the dye moiety. The linker is linked to the DHHA via an ester bond (ester-linked statin derivative or ELSD), or via an amide bond (amide-linked statin derivative or ALSD). Thus linked to the DHHA, the linker provides a relatively stable link either for essentially no hydrolysis/statin release after administration, or preferably for very slow hydrolysis and statin release, as is the case for the ELSD. Embodiments include methods to provide the desired THSD, in particular the ELSD, with the DHHA in its open chain form. The invention also relates to methods wherein one or more ELSD is administered to a patient in a therapeutically effective amount, and methods wherein an ELSD and an ALSD are co-administered in a coordinated administration schedule. Advantages of the THSD and their use include, among others, improved efficacy and dose-response, and decreased statin-associated side effects.

  这项发明通常涉及肿瘤靶向他汀衍生物（THSD）及其在治疗中的应用，特别是癌症治疗。这些THSD包括三个部分：他汀部分，其中包括一个由酯键固定在其开链形式中的二羟基庚酸单元（DHHA），一个庚甲基碳氰染料（HMCD）部分，以及将他汀的DHHA与染料部分结合的连接物。连接物通过酯键（酯键结合他汀衍生物或ELSD）或酰胺键（酰胺键结合他汀衍生物或ALSD）与DHHA连接。因此，连接到DHHA的连接物提供了一个相对稳定的连接，要么在给药后基本不发生水解/他汀释放，要么更好地进行非常缓慢的水解和他汀释放，就像ELSD的情况一样。实施例包括提供所需的THSD，特别是ELSD，其中DHHA处于其开链形式。该发明还涉及其中一个或多个ELSD以治疗有效剂量的方式给患者施用的方法，以及其中ELSD和ALSD在协调的给药时间表中联合给药的方法。THSD及其使用的优点包括，但不限于，改善疗效和剂量反应，以及减少与他汀相关的副作用。
• Perivascular wraps
  申请人：Gravett M David

  公开号：US20080085855A1

  公开（公告）日：2008-04-10

  The present invention provides compositions, devices, and methods for maintaining or improving the integrity of body passageways following surgery, such as at a graft site, or injury. Delivery devices including one or more therapeutic agents and a mesh are described. Representative examples of therapeutic agents include microtubule stabilizing agents, anti-angiogenic factors, inhibitors of smooth muscle cell growth or proliferation, non-steroidal anti-inflammatory drugs, and other factors useful preventing and/or reducing a proliferative biological response that may obstruct or hinder the optimal functioning of the passageway or cavity.

  本发明提供了维持或改善手术后身体通道完整性的组合物、装置和方法，例如在移植部位或受伤处。描述了包括一个或多个治疗剂和网状物的输送装置。治疗剂的代表性例子包括微管稳定剂、抗血管生成因子、平滑肌细胞生长或增殖抑制剂、非甾体抗炎药和其他有用的因子，用于预防和/或减少可能阻碍或妨碍通道或腔体的最佳功能的增殖生物反应。
• Taxane coatings for implantable medical devices
  申请人：Reyes Priscilla

  公开号：US20070212394A1

  公开（公告）日：2007-09-13

  This disclosure relates to implantable medical devices coated with a taxane therapeutic agent, such as paclitaxel, in one or more solid form(s) having varying dissolution rates. Particularly preferred coatings comprise amorphous and/or solvated solid forms of taxane therapeutic agents that provide durable coatings that release the taxane over a desired period of time, which can be varied in the absence of a polymer by selecting the type and amount of solid forms of the taxane therapeutic agent in the coating. Other preferred embodiments relate to methods of coating medical devices and methods of treatment. The coatings can provide a sustained release of the taxane therapeutic agent within a body vessel without containing a polymer to achieve the desired rate of paclitaxel elution.

  本公开涉及涂有紫杉醇治疗剂（如紫杉醇）的植入式医疗器械，其具有不同溶解速率的一个或多个固态形式的涂层。特别优选的涂层包括无定形和/或溶剂化的紫杉醇治疗剂的固态形式，其提供持久的涂层，可以在不含聚合物的情况下通过选择涂层中的治疗剂的固态形式的类型和数量来改变所需的释放时间。其他优选实施例涉及涂覆医疗器械的方法和治疗方法。这些涂层可以在不含聚合物的情况下提供紫杉醇治疗剂的持续释放，以达到所需的紫杉醇溶出速率。
• Compositions and methods for treating or preventing inflammatory diseases
  申请人：Angiotech Pharmaceuticals, Inc.

  公开号：US20020183380A1

  公开（公告）日：2002-12-05

  Methods and compositions for treating or preventing inflammatory diseases such as psoriasis or multiple sclerosis are provided, comprising the step of delivering to the site of inflammation an anti-microtubule agent, or analogue or derivative thereof.

  提供了用于治疗或预防炎症性疾病如银屑病或多发性硬化的方法和组合物，包括将抗微管蛋白剂或其类似物或衍生物输送至炎症部位的步骤。
• Compositions and methods for treating or preventing diseases of body passageways
  申请人：Hunter L. William

  公开号：US20050096388A1

  公开（公告）日：2005-05-05

  The present invention provides methods for treating or preventing diseases associated with body passageways, comprising the step of delivering to an external portion of the body passageway a therapeutic agent. Representative examples of therapeutic agents include anti-angiogenic factors, anti-proliferative agents, anti-inflammatory agents, and antibiotics.

  本发明提供了用于治疗或预防与身体通道相关的疾病的方法，包括将治疗剂递送到身体通道的外部部分。治疗剂的代表性例子包括抗血管生成因子、抗增殖剂、抗炎剂和抗生素。